Nicole Sinclair is research director, Mad Money and Jim Cramer's researcher at TheStreet. Nicole analyzes stocks and develops a strategic macro outlook, which she incorporates into segment ideas for CNBC's "Mad Money" and supports Jim's other endeavors including "Squawk on the Street" and RealMoney.com. Nicole also writes the "Inside the Madness" blog on cnbc.com.
Previously, she worked as an investment banking analyst for the Industrials Group in Goldman Sachs' New York office. Born and raised in Princeton, New Jersey, Nicole graduated with honors from Harvard College, where she served as executive editor of The Harvard Crimson.
Follow Nicole Sinclair on Twitter @nicoleusinclair.
From retail to restaurants, "Mad Money" host Jim Cramer is naming his top buys in the wake of the Dow hitting 18K.
As the U.S. reduces its military budget, Jim Cramer sees allied countries are arming themselves. This is good news for one group of stocks.
The biotech sector has made a drastic change in the past few days. Jim Cramer goes off the charts to find out if they could be headed down further.
With such awesome GDP data announced Tuesday, Cramer gives the inside scoop on which stocks fund managers will be buying as a result.
Grab the latest CNBC gear from the NBCUniversal Store!
Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.
You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.